BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. announced that they have completed their business combination to form Amneal Pharmaceuticals, Inc. As a diversified company with a robust generics business, Amneal is now the 5th largest generics business in the United States, with a growing, high-margin specialty franchise. Shares of Impax ceased trading
NEW YORK — Merger partners Amneal Pharmaceuticals LLC and Impax Laboratories Inc. have tabbed Robert Stewart, executive vice president and chief operating officer of Allergan plc, to lead the combined company. Plans call for Stewart to join Amneal as president effective Jan. 25. After Amneal and Impax finalize their merger, announced in mid-October, he will
BRIDGEWATER, N.J. — Amneal Biosciences is set to roll out triamcinolone acetonide injectable suspension 40 mg/ml, a steriod used to treat inflammation. Amneal said its triamcinolone acetonide product will be the only AP-rated generic equivalent injectable suspension available, with just the Kenalog-40 brand from Bristol-Myers Squibb currently on the market. “This important launch demonstrates the
NEW YORK — Amneal Pharmaceuticals LLC and Impax Laboratories Inc. plan to merge in an all-stock transaction. An Amneal-Impax merger would create the fifth-largest generics supplier by gross revenue in the United States. To be named Amneal Pharmaceuticals Inc., the new entity will also possess a growing, high-margin specialty drug franchise. Financial terms of the deal
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC next month plans to begin shipping Yuvafem 10-mcg estradiol vaginal inserts, a treatment for menopausal symptoms. Amneal said Monday that its product represents the first generic equivalent of Vagifem from Novo Nordisk. Yuvafem delivers the same low dose of vaginal estrogen in a preloaded, single-use, disposable applicator. Amneal said
BRIDGEWATER, N.J. — Amneal Pharmaceuticals has been recognized as a top generic drug manufacturer by the Healthcare Distribution Alliance (HDA). Amneal said that this week it received the Distribution Industry Award for Notable Achievements in Healthcare (DIANA) for Generic Pharmaceutical Product Manufacturer, for the $100 million-plus sales to health care distributors category. HDA presented the
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has launched diclofenac sodium topical gel 1%, a pain reliever for osteoarthritis, in the United States. Amneal said its product, available in a 100-gram tube, is a first-to-market generic version of Voltaren Gel from Endo International plc and has begun shipping through wholesalers and directly to the trade. “We are
BRIDGEWATER, N.J. — Amneal Pharmaceuticals won the award for “Company of the Year, Americas” at the 2015 Global Generics and Biosimilars Awards held in Madrid, Spain. Amneal said late Thursday that it was the second straight year the company was recognized by Generics Bulletin, a global newsletter for the generic drug and biosimilars industries. In
BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has formed Amneal Biosciences, a new business unit. Amneal said Tuesday that the new subsidiary will focus exclusively on the commercialization of high-barrier-to-entry generic drugs and specialty pharmaceuticals — such as injectables, oncologics and biosimilars — health care providers worldwide. “Having a dedicated company focused on the unique needs and
